polyinosinic-polycytidylic acid + atezolizumab

This drug is a **combination of polyinosinic-polycytidylic acid (poly I:C) and atezolizumab**. Polyinosinic-polycytidylic acid is a synthetic double-stranded RNA that acts as an agonist for toll-like receptor 3 (TLR3) and retinoic acid-inducible gene I-like receptors (RIG-I, MDA5), stimulating the innate immune response, enhancing adaptive immune functions, acting as a vaccine adjuvant, and promoting antitumor activity through type I interferon induction and direct apoptosis in some cancer cells[2][4]. Atezolizumab is a monoclonal antibody immune checkpoint inhibitor that targets programmed death-ligand 1 (PD-L1), thereby blocking its interaction with PD-1 and B7.1 receptors on T cells and antigen-presenting cells, facilitating immune-mediated tumor cell killing[1]. The combination is under investigation as a novel immunotherapy for solid tumors, aiming to potently augment immune response by leveraging the immune-priming effects of poly I:C with the checkpoint blockade provided by atezolizumab[3].